Lara Meisner sold $182k of BCAX
Chief Legal Officer at Bicara Therapeutics Inc.. 15,829 shares at an average of $11.49, traded Sep 15, 2025, filed Sep 17, 2025.
Score components
- +15RoleOfficer
- +12Trade size$182k at market
- +20Share of holdings soldSold 100% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001883986-25-000006, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 15, 2025 | MOption exercise Common Stock10b5-1 | +15,829 | $5.45 | $86k | 15,829 | Sep 17, 2025 |
| Sep 15, 2025 | SOpen-market sale Common Stock10b5-1 | -15,829 | $11.49 | $182k | 0 | Sep 17, 2025 |
| Sep 15, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -6,085 | $0.00 | $0 | 54,769 | Sep 17, 2025 |
| Sep 15, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -9,744 | $0.00 | $0 | 87,699 | Sep 17, 2025 |
Related signals
Other insiders at Bicara Therapeutics Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 6Weak | Bicara Therapeutics Inc. | Ryan Cohlhepp President, COO & Interim CEO | $401k 17,500 shares | -9% | |
| 6Weak | Bicara Therapeutics Inc. | Ivan Hyep Chief Financial Officer | $168k 9,200 shares | -6% | |
| 6Weak | Bicara Therapeutics Inc. | Ryan Cohlhepp President and COO | $234k 12,500 shares | -6% | |
| 13Weak | Bicara Therapeutics Inc. | Ryan Cohlhepp President and COO | $226k 12,500 shares | -6% | |
| 22Weak | Bicara Therapeutics Inc. | Ivan Hyep Chief Financial Officer | $341k 18,400 shares | -13% | |
| 32Weak | Bicara Therapeutics Inc. | Claire Mazumdar Chief Executive Officer | $776k 41,163 shares | -12% | |
| 17Weak | Bicara Therapeutics Inc. | David Raben Chief Medical Officer | $205k 11,000 shares | -27% | |
| 22Weak | Bicara Therapeutics Inc. | Claire Mazumdar Chief Executive Officer | $454k 24,103 shares | -7% | |
| 13Weak | Bicara Therapeutics Inc. | Ryan Cohlhepp President and COO | $227k 12,500 shares | -6% | |
| 22Weak | Bicara Therapeutics Inc. | Claire Mazumdar Chief Executive Officer | $467k 24,734 shares | -8% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.